EUCTR2007-005769-36-GB进行中（未招募）不适用
A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovir DF) on an Empty Stomach - ONCE - Only Nocturnal Combination Evaluation
Gilead Sciences Limited0 个研究点开始时间: 2008年3月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must have documented HIV-1 infection by Roche Amplicor® (Version 1.5
- •Ultra-sensitive) or equivalent assay – either at screening or previously documented in the patient’s medical record.
- •Stable HAART regimen of efavirenz, emtricitabine and tenofovir DF or Truvada and
- •efavirenz for = 24 weeks prior to Screening. (Subjects can have been previously treated with tenofovir DF, lamivudine, and efavirenz or tenofovir DF, emtricitabine, and efavirenz prior to switching to Truvada and efavirenz. They must have switched in order to simplify his/her HAART regimen and must not have had a treatment interruption prior to the switch).
- •Undetectable plasma HIV-1 RNA (< 50 copies/mL) at Screening and =12 weeks prior to Screening).
- •=18 years old
- •Adequate renal function by:
- •- Estimated creatinine clearance =60 mL/min according to the Cockcroft Gault formula
- •Hepatic transaminases (AST and ALT) = 5 x upper limit of normal (ULN)
- •Total bilirubin = 1.5 mg/dL
- •Adequate hematologic function (absolute neutrophil count =1,000/mm3; platelets =25,000/mm3; hemoglobin =8.0 g/dL
- •Serum amylase = 1.5 x ULN (subjects with serum amylase > 1.5 x ULN will remain eligible if serum lipase is = 1.5 x ULN)
- •Negative serum pregnancy test (females of childbearing potential only i.e., not surgically sterile or at least two years post-menopausal)
- •Women of childbearing potential (WOCBP) must be willing to use two methods of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drugs in such a manner that the risk of pregnancy is minimized.
- •Female subjects who utilize hormone contraceptive as one of their birth control methods must have used the same methods for at least three months prior to study dosing.
- •Female subjects who are postmenopausal for less than two years are required to have FSH = 40 mIU/mL. If the FSH is < 40 mIU/mL, the subject must agree to use highly effective method of birth control (as described above) to participate in the study
- •Male subjects who are sexually active must be willing to use effective barrier contraception (e.g., condom with spermicide) during heterosexual intercourse from screening through completion of the study and continuing for up to 12 weeks after the last dose of study drugs
- •Life expectancy =1 year
- •The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who have been treated with any ARV other than Truvada, tenofovir DF,
- •emtricitabine, lamivudine or efavirenz
- •Known hypersensitivity or toxicities to emtricitabine (FTC), tenofovir DF (TDF) or
- •Known hypersensitivity or toxicities to lamivudine (3TC) if the subject initiated HAART with tenofovir DF, lamivudine, and efavirenz
- •Known hypersensitivity or toxicities to Sustiva
- •Have a history of resistance to any of the study agents at the time of screening (documented presence of resistance mutation(s) as defined by the IAS-USA 2005 Guidelines
- •A new AIDS-defining condition diagnosed within the 30 days prior to the Baseline visit.
- •Pregnant or lactating or breastfeeding females
- •Severe hepatic impairment (> 5 times upper limit of normal as defined by laboratory transaminases) or deemed clinically significant by investigator.
- •Any current know clinical or laboratory parameter of GSI grade 4. However asymptomatic grade 4 abnormalities will be permitted at the discretion of the investigator if deemed clinically appropriate (excluding AEs and laboratory parameters mentioned elsewhere in the inclusion/exclusion criteria). Abnormalities deemed insignificant by the investigator must be discussed with the sponsor prior to enrollment.
- •Receiving on-going therapy with any of the prohibited medications. Administration of any of the medications must be discontinued at least 30 days prior to the Baseline visit and for the duration of the study period.
- •Active, serious infections (other than HIV infection) requiring parenteral antibiotic therapy within 30 days prior to Screening visit.
- •Current acute illness or infection (e.g., opportunistic) – including an active AIDS defining condition within the previous six months.
- •Hepatitis B co-infection or Hepatitis C co-infection
- •Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS with 30 days of Baseline visit and are not anticipated to require systemic therapy during the study.
- •Prior history of renal or bone disease deemed significant by the investigator.
- •Subjects currently taking part in any other clinical trial using an investigational product, with the exception of studies where the treatment studied has been stopped for more than 1 month.
- •Evidence of alcohol and/or drug or substance abuse that in the judgment of the investigator would likely result in the patient being unreliable in fulfilling the conditions of the protocol.
- •History of psychological illness or conditions that in the judgment of the investigator might interfere with the patient’s ability to understand the requirements of the study.
- •Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements and cause the patient to be unable to complete the study protocol.
研究者
相似试验
招募中
4 期
A postmarketing surveillance to study how safe, tolerable, preferred and effective is Mesalo foam (Mesalazine rectal foam 1 gm) in treatment of patients with ulcerative colitis.CTRI/2016/01/006545Cipla Ltd120
进行中（未招募）
1 期
A Phase IV, prospective, open-label, uncontrolled, single-centre cohort trial to be conducted in Norway to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 mg/kg/day for 7 days. - Response to Kuvan® in subjects with PKU from a single centre in NorwayHyperphenylalaninemia (HPA) in adults and children >=16 years of age with phenylketonuri (PKU) (classic or mild PKU, or mild hyperphenylalaninemia (HPA)).MedDRA version: 9.1Level: LLTClassification code 10034872Term: PhenylketonuriaMedDRA version: 9.1Level: LLTClassification code 10034873Term: Phenylketonuria (PKU)MedDRA version: 9.1Level: PTClassification code 10034872Term: PhenylketonuriaMedDRA version: 9.1Level: LLTClassification code 10034871Term: PhenylalaninemiaEUCTR2009-012978-12-NOMerck Serono, an affiliate of E. Merck AB
进行中（未招募）
1 期
An open label study to Evaluate Efficacy, Safety and Mucosal Healing of early versus late use of vedolizumab in ulcerative colitis: the LOVE-UC study (LOw countries VEdolizumab in UC study) LOVE-UClcerative colitisEUCTR2014-005443-40-NLAcademic Medical Center/ Gastroenterology120
进行中（未招募）
1 期
Study of efficacy and safety of ranibizumab in patients with wet age related macular degeneration that have previously been treated with aflibercept.EUCTR2014-001085-10-DEovartis Pharmaceuticals UK Ltd124
已完成
4 期
A prospective Phase IV study at different centers without any competitor,Single dose clinical study to assess the safety and efficacy of glabellar lines DYSPORT® in adult subjects for treatment of glabellar lines moderate-to-severe the area on frontal bone above the nose and between the eyebrowsCTRI/2018/11/016357Cliniexperts Services Private Limited105